🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-523839-18-00
Authorised Phase I

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Deucravacitinib tablets 6 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with SOTYKTU (deucravacitinib) tablets 6 mg, Distributed by Bristol-Myers Squibb Company, Princeton, New Jersey 08543 USA, in healthy, adult, human subjects under fed condition

2025-523839-18-00 · tracked via the Priya Life Science EU tracker
Sponsor
Sun Pharmaceutical Industries Limited
Sponsor type
Pharmaceutical company
Therapeutic area
Immune System Diseases
Decision date
19/02/2026
Enrollment target
40
Sites
Romania

Condition studied

plaque psoriasis

Eligibility

Age group
18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-523839-18-00 on CTIS ↗ ← All trials in the EU